The company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...

Indian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...

Zydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...

In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...

Zydus Lifesciences has partnered with RK Pharma Inc of the US. They will collaborate on a new sterile injectable oncology supportive care p...

As per the report by the USFDA, Zydus Pharmaceuticals (USA) Inc, is recalling 2,880 bottles of Carvedilol tablets, USP 25 mg in the US due ...

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

UCB alongwith others has filed separate cases against as many as 15 drug makers for allegedly infringing its patented drug Vimpat.

Ahmedabad-based Zydus Cadila says, it agreed to settle a patent litigation suit with US-based Somaxon Pharmaceuticals for insomnia drug – S...

Zydus Cadila has acquired 100% stake in Mumbai-based Biochem Pharmaceuticals for an undisclosed amount.

The deal is expected to be valued at Rs 300-450 cr and will boost Biochem's revenue growth. In fiscal 2009-10, Biochem reported revenues of...

Ahmedabad-based Zydus Cadila today said its consolidated net profit rose by 15.38 per cent to Rs 229.82 crore in the first quarter ended Ju...

Zydus Cadila plans to acquire US-based generic pharma company. The Ahmedabad-based firm signed an asset purchase agreement with a US-based ...

The company is in talks with 2-3 pharma companies and has earmarked an investment of about $25 million for its expansion plans in Japan.

Cadila Healthcare Ltd on Monday announced the foray of Zydus group into the generic market of Japan and the establishment of a wholly owned...